Sign In
Buy GHRS
$28.07
-0.310 (-1.09%)
At Close: Jul 31, 2026
Why Is GH Research Stock Trading Higher on Thursday?
12:36pm, Thursday, 16'th Jul 2026
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a
CleanSpark shares surge after company secures $6.6B data center lease agreement
07:53am, Tuesday, 14'th Jul 2026
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
07:20am, Tuesday, 14'th Jul 2026
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
03:18pm, Monday, 13'th Jul 2026
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Je
GH Research Announces Publication of Phase 2a Postpartum Depression Results
07:00am, Thursday, 04'th Jun 2026
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance o
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
04:07am, Wednesday, 20'th May 2026
GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the
These Analysts Revise Their Forecasts On GH Research After Q1 Results
10:58am, Friday, 15'th May 2026
GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
07:00am, Thursday, 14'th May 2026
Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study en
GH Research Announces Pricing of $117.5 Million Underwritten Offering
08:00am, Wednesday, 29'th Apr 2026
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
09:48am, Tuesday, 21'st Apr 2026
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
09:00am, Monday, 20'th Apr 2026
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
08:35am, Monday, 20'th Apr 2026
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews
Psychedelics stocks rise after Trump order expands research, access pathways
05:56am, Monday, 20'th Apr 2026
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)
04:27am, Wednesday, 15'th Apr 2026
Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two busi
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing
